Inclusion Criteria:

- Age >= 18 years old

- ECOG performance status 0-2

- Non-squamous cell type non-small cell lung cancer (NSCLC)

- Stage IV, Stage IIIB cannot be treated with curative intent or Relapsed after surgery
or radiation therapy

- No prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation
treatment. The last dose of adjuvant chemotherapy should be at least 6 months earlier
from randomization, and the regimen should not contain docetaxel or pemetrexed.

- No prior immunotherapy, biologic therapy

- Measurable lesion with Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1

- Hemoglobin >=9.0g/dl, Platelet >=100,000/uL, neutrophil >=1,500 /uL Creatinine <=1.5
x upper normal limit or creatinine clearance >=60 mL/min Bilirubin <=1.5 x upper
normal limit, Transaminases <=2 x upper normal limit Alkaline phosphatase <=2 x upper
normal limit

- Written informed consent

Exclusion Criteria:

- Pregnancy, Lactating woman

- Woman in child bearing age who refuses to do pregnancy test

- Moderate or greater than grade 1 motor or sensory neurotoxicity

- Hypersensitivity to taxane

- Comorbidity or poor medical conditions

- Other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in
situ)

- Concurrent treatment with other investigational drugs within 30 days before
randomization

- Active treatment with other anticancer chemotherapy

- EGFR mutation (exon 19 deletion, L858R, L861Q, G719A/C/S)